EUVIMEDEUVIMED entdecken
Crossref

mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response

Toshifumi Tada iD, Takashi Kumada iD, Atsushi Hiraoka iD, Kazuya Kariyama iD, Satoshi Yasuda, Fujimasa Tada, Hideko Ohama iD, Kazuhiro Nouso, Tomomitsu Matono, Shinichiro Nakamura, Hidenori Toyoda iD, Real‐life Practice Experts for HCC (RELPEC) Study Group

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Toshifumi Tada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Sustained Virologic Response, alpha-Fetoproteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The study aims to develop a novel predictive model including the fibrosis (FIB)‐3 index for hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) who achieved sustained virological response (SVR) with direct‐acting antiviral (DAA) therapy.

Methods

This study included 2529 patients in whom HCV was eradicated with DAA therapy. The after DAA recommendation for surveillance (ADRES) score, which is based on sex, FIB‐4 index, and α‐fetoprotein, was used to predict HCC development. We developed a modified ADRES (mADRES) score, in which the FIB‐4 index was replaced by the FIB‐3 index, and evaluated its usefulness in predicting HCC development compared with the ADRES score.

Results

In the training set ( n = 1770), multivariate analysis with Cox proportional hazards modeling showed that male sex (hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.48–3.01), FIB‐3 index (HR, 1.36; 95% CI, 1.28–1.45), and α‐fetoprotein (HR, 1.05; 95% CI, 1.03–1.07) are independently associated with HCC development. The incidence of HCC differed significantly by ADRES or mADRES score in multiple comparisons. Univariate Cox proportional hazards models showed that compared with the mADRES score 0 group, the HR for HCC development was 2.07 (95% CI, 1.02–4.19) for the mADRES score 1 group, 11.37 (95% CI, 5.80–22.27) for the mADRES score 2 group, and 21.95 (95% CI, 10.17–47.38) for the mADRES score 3 group. Similar results were obtained for mADRES score but not for ADRES score in the validation set ( n = 759).

Conclusion

The mADRES score is useful for predicting HCC development after SVR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsSustained Virologic Responsealpha-FetoproteinsAntiviral AgentsHepatitis C, ChronicHumansMaleFemaleMiddle AgedAgedProportional Hazards ModelsPredictive Value of TestsSex Factors

Stichwörter der Autor:innen

direct‐acting antiviralhepatitis C virushepatocellular carcinomamADRES scoresustained virological response

Substanzen

alpha-FetoproteinsAntiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Department of Nursing, Gifu Kyoritsu University, Gifu, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Department of Internal Medicine, Himeji St. Mary's Hospital, Himeji, Japan.

ORCID-Profile: Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Hideko Ohama, Hidenori Toyoda

Zitieren

APA

Tada, T., Kumada, T., Hiraoka, A., Kariyama, K., Yasuda, S., Tada, F., Ohama, H., Nouso, K., Matono, T., Nakamura, S., Toyoda, H., & Real‐life Practice Experts for HCC (RELPEC) Study Group (2024). mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16512

Vancouver

Tada T, Kumada T, Hiraoka A, Kariyama K, Yasuda S, Tada F, et al. mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16512

BibTeX
@article{Tada2024,
  author = {Tada, Toshifumi and Kumada, Takashi and Hiraoka, Atsushi and Kariyama, Kazuya and Yasuda, Satoshi and Tada, Fujimasa and Ohama, Hideko and Nouso, Kazuhiro and Matono, Tomomitsu and Nakamura, Shinichiro and Toyoda, Hidenori and Real‐life Practice Experts for HCC (RELPEC) Study Group, Real‐life Practice Experts for HCC (RELPEC) Study Group},
  title = {mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16512}
}
Kostenlos starten →